Onkologie. 2012:6(5):260-265

Patients with multiple cancers of head and neck

Edvard Geryk1, Jiří Kozel2, Theodor Horváth1, Petr Kubíček2
1 Fakultní nemocnice, Brno
2 Geografický ústav Přírodovědecké fakulty Brno

A total of 20,855 head and neck cancers (HNC), based in the Czech Cancer Registry in 1976–2005, there were notificated 4,912 multiple

cancers, of which were 3,679 (74.9 %) in males and 1,233 (25.1 %) in females, i.e. 17.6 % cases in males and 19.5 % in females of total HNC,

affected by other neoplasms. There were 56.3 % primary and 43.7 % subsequent HNC in males, 43.8 % and 56.2 % in females. The number

of primary HNC incerased during the first decade and then decreased, the number of subsequent HNC increased steadily. A total of 14

Czech regions were distributed 51.6 % multiple HNC in five regions (Northern and Southern Moravia, Prague, Southern and Central Bohemia).

The most frequent were 28.8 % multiple cancers of lips, 11.9 % of tonsils, 11.1 % of parotid gands. The primary 2,070 HNC in males

were followed by 2,436 other neoplasms in the average interval 6.7 years; the primary 540 HNC in females were followed by 649 other

neoplasms in males in the average interval 6.9 years. The most frequent diagnoses of 425 synchronous cases were cancers of respiratory

tract, skin and other HNC, of 2,660 metachronous cases were cancers of skin, respiratory and digestive tract. The subsequent 2.302

HNC were preceded by 2.858 other neoplasms with the most frequent cancers of skin, respiratory tract and other HNC. The expected

low representation of advanced clinical stages was not confirmed. Of 2,436 subsequent neoplasms in males and 649 in females were

registered after early HNC stages in 16.1 % males and 18.6 % females of stages I, II, in 10.7 % males and 7.8 % females of stages III, IV; after

advanced HNC stages were in 8.2 % males and 6.5% females of stages I, II, in 8.9 % males and 5.2 % females of stages III, IV; the unknown

stages represented 56.1 % in males and 61.9 % in females of subsequent neoplasms. All 729 subsequent advanced cancers (606 males,

123 females) represented 3.5 % of total registered cases of HNC during 30 years and about 1,540 patients with HNC affected by other

subsequent cancer of 43,850 HNC based in the Czech Cancer Registry during half-century. Up to Oct. 2007, of the primary HNC 14.7 %

males and 20.6 % females survived, and those 85.3 % males and 79.4 % females died. Nearly 8,000 patients is estimated to be treated for

HNC, some of them with multiple cancers, in the Czech Republic in 2015. Will be reached their expected numbers?

clinical stages.

Keywords: head and neck cancers, multiple occurrence, distribution by age, time, space, synchronous and metachronous cancers,

Published: November 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Geryk E, Kozel J, Horváth T, Kubíček P. Patients with multiple cancers of head and neck. Onkologie. 2012;6(5):260-265.
Download citation

References

  1. Geryk E, Horváth T, a kol. Zátěž nádory u české populace na pozadí demografie a ekonomiky. ČLČ, 2013; v tisku.
  2. ÚZIS: Novotvary 2009 ČR. ÚZIS ČR, 2012: 264, www.uzis.cz.
  3. Konečný M, Geryk E, Kubíček P, kol. Prevalence nádorů v České republice, 1989-2005-2015. Brno: PřF MU, 2008: 69.
  4. Veness M. Lip cancer: important management issues. Australas J Dermatol 2001; 142(1): 30-32. Go to original source... Go to PubMed...
  5. de Visscher JG, van der Waal I. Etiology of cancer of the lip. A review. Int J Oral Maxillofac Surg 1998; 27(3): 199-203. Go to original source... Go to PubMed...
  6. Moore S, Johnson N, Pierce A, et al. The epidemiology of lip cancer: a review of global incidence and aetiology. Oral Dis 1999; 5(3): 185-195. Go to original source... Go to PubMed...
  7. Brown LM, McCarron P, Freedman DM. New malignancies following cancer of the buccal cavity and phyranx. In: Curtis RE at al. New malignancies among cancer survivors: SEER cancer registries 1973-2000. Bethesda (MD), Nat Canc Inst 2006: 15-57.
  8. Winn DM, Blot WJ. Second cancer following cancers of the buccal cavity and pharynx in Connecticut, 1935-1982. Natl Cancer Inst Monogr 1985; 68: 25-48. Go to PubMed...
  9. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63(1-3): 8-18. Go to original source... Go to PubMed...
  10. Brennan P, Coates M, Armstrong B, et al. Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia. Br J Cancer 2000; 82(7): 1344-1347. Go to original source... Go to PubMed...
  11. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Egl J Med 1997; 336: 897. Go to original source... Go to PubMed...
  12. Forastiere A, Koch W, Trotti A, et al. Head and neck cancer. N Engl J Med 2001; 345(26): 1890-1900. Go to original source... Go to PubMed...
  13. Franceschi S, Levi F, La Vecchia C, et al. Comparison of the effect of smoking and alcohol drinking between oral and pharyngeal cancer. Int J Cancer 1999; 83(1): 1-4. Go to original source... Go to PubMed...
  14. Brown LM, Gridley G, Diehl SR, et al. Family cancer history and susceptibility to oral carcinoma in Puerto Rico. Cancer 2011; 92(8): 2102-2108. Go to original source...
  15. Hemminki K, Jiang Y, Dong C. Second primary cancers after anogenital, skin, oral, esophageal and rectal cancers: etiological links? Int J Cancer 2001; 93(2): 294-298. Go to original source... Go to PubMed...
  16. Rafferty MA, O'Dwyer TP. 2001. Secondary primary malignancies in head and neck squamous cell carcinoma. J Laryngol Otol 2001; 115(12): 988-991. Go to original source... Go to PubMed...
  17. Herrero R, Castellsague X, Pawlita M, et al. 2003. Human papillomavirus and oral cancer: the IARC multicenter study. J Natl Cancer Inst 2003; 95(23): 1772-1783. Go to original source... Go to PubMed...
  18. Gillison ML, Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 2003; 31: 57-65. Go to original source... Go to PubMed...
  19. Shrestha P, Huang JW, et al. Primary epithelial tumors of salivary glands, histogenesis, histomorphological and immunohistochemical implications, diagnosis and clinical management. Crit Rev Oncol Hematol 1996; 23(3): 239-260. Go to original source... Go to PubMed...
  20. Saku T, Hayashi Y, Takahara O, et al. Salivary gland tumors among atomic bomb survivors, 1950-1987. Cancer 1997; 79(8): 1465-1475.
  21. Modan B, Chetrit A, Alfandary E, et al. Increased risk of salivary gland tumors after low-dose irradiation. Laryngoskope 1998; 108(7): 1095-1097. Go to original source... Go to PubMed...
  22. Horn-Ross PL, Ljung BM, Morrow M. Environmental factors and the risk of salivary gland cancer. Epidemiology 1997; 8(4): 414-419. Go to original source... Go to PubMed...
  23. Swanson GM, Burns PB. Cancers of the salivary gland: workplace risks among women and men. Ann Epidemiol 1997; 7(6): 369-374. Go to original source... Go to PubMed...
  24. Hayes RB, Bravo-Otero E, Kleinman DV, et al. Tobacco and alcohol use and oral cancer in Puerto Rico. Cancer Cause Control 1999; 10(1): 27-33. Go to original source... Go to PubMed...
  25. McDermott AL, Dutt SN, Watkinson JC. The aetiology of nasopharyngeal carcinoma. Clin Otolaryngol Allied Sci 2001; 26(2): 82-92. Go to original source... Go to PubMed...
  26. Geryk E, Dítě P, Trna J, Kozel J, kol. Klinická stadia u nemocných s vícečetnými novotvary. Onkologie 2010; 4(6): 357-361.
  27. Geryk E, Dítě P, Kozel J, kol. Nádorové multiplicity u české populace. Čas Lék Čes 2010; 149(4): 178-183.
  28. Billroth T, Winiwarter A. Die allgemeine chirurgische Pathologie und Therapie. Berlin, G. Reimer, 1889: 971.
  29. American Cancer Society. Cancer Facts & Figures 2009, No. 500809, Atlanta: American Cancer Society; 2009: 24-41.
  30. Geryk E, Dítě P, Sedláková L. kol. Trend vícečetných nemelanomových nádorů kůže z pohledu jejich epidemiologie. Dermatologie pro praxi 2010; 4(1): 5-9.




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.